• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Promius launches isotretinoin product, program


Promius Pharma has launched Zenatane (isotretinoin) capsules for the treatment of acne vulgaris.


Promius Pharma has launched Zenatane (isotretinoin) capsules for the treatment of acne vulgaris.

A spokeswoman for Promius noted the Food and Drug Administration has indicated that Zenatane is rated as an A/B equivalent to Accutane, the isotretinoin product formerly manufactured by Roche.

Zenatane will also be supported by the Promius Promise, a pharmacy service designed to support both physicians and patients, according to a news release. Promius Promise provides information to patients about treatment requirements and reminders, has staff available to answer questions about the drug, and can deliver Zenatane to patients within 24 hours.

Additionally, the Promius Promise provides payment assistance for patients both with and without insurance. To support the Promius Promise, Promius partnered with an accredited pharmacy that is iPLEDGE-certified.

“The majority of dermatologists believe isotretinoin can make an enormous contribution to the quality of life of a patient with severe recalcitrant nodular acne,” Promius head of sales and marketing, Rob D’Urso, stated in a news release. “Yet, based on an FDA review of year five of the iPLEDGE program, over 400,000 attempts to fill isotretinoin prescriptions were denied due to failures to meet iPLEDGE requirements. We hope the Promius Promise can help.”

Related Videos
© 2023 MJH Life Sciences

All rights reserved.